Tests INCB123667 in ovarian cancer that returned after platinum treatment
Tests the drug INCB123667 in adults with ovarian cancer that has high cyclin E1.
Plain-language title generated from the registry record
Registry title: A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Key facts
- Where
- Bellinzona, Chur, Geneva, and Lausanne, SwitzerlandSee the 4 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 99 years old?
Source: NCT07023627, who can take part
Where in Switzerland
- Istituto Oncologico Della Svizzera Italiana (Iosi) Di BellinzonaBellinzona, SwitzerlandTaking people
- Kantonsspital GraubundenChur, SwitzerlandTaking people
- Geneva University Hospitals-HugGeneva, SwitzerlandTaking people
- Centre Hospitalier Universitaire Vaudois Lausanne (Chuv) - Centre Du Cancer Lausanne-Batiment HospitLausanne, SwitzerlandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Incyte Corporation
- Trial code
- NCT07023627EU 2025-521513-14-00
- Record updated
- 15 September 2026
- Original description
This study will evaluate the safety and efficacy of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer (PROC) With Cyclin E1 Overexpression.Read full original descriptionShow less
A Phase 2, Single-Arm Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression (MAESTRA 1)
This study will evaluate the safety and efficacy of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer (PROC) With Cyclin E1 Overexpression.
Inclusion: Histological diagnosis of a high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer; Have platinum-resistant disease:; Participants who have only had 1 line of platinum-based therapy must have received at least 4 cycles of a platinum-containing regimen; Participants who have received 2 to 4 lines of platinum-based therapy must have progressed on or within 6 months after the last dose of platinum; Willingness to undergo a pretreatment biopsy. Note: Tissue from a fresh pretreatment biopsy is preferred, however an archival sample is acceptable as long as the sample is no older than 5 years; Received at least 1 and no more than 4 prior lines of systemic therapy following the initial diagnosis, after which single-agent therapy is considered an appropriate next therapeutic option; Must have received bevacizumab unless there was a contraindication for its use; If the tumor tests positive for FRα, participants must have received mirvetuximab soravtansine unless there is an exception for its use on medical grounds.
Exclusion: The tumor tests positive for FRα but the participant has not received mirvetuximab soravtansine for any reason other than medical contraindication; Clinically significant or uncontrolled cardiac disease within 6 months before the first dose of study drug; Have endometrioid, clear cell, mucinous, or sarcomatous histology, mixed tumors containing any of these histologies, or low-grade/borderline ovarian cancer; Have primary platinum-refractory disease: either did not respond (CR or PR) to first-line platinum-containing therapy or progressed on or within 3 months after the last dose of the first line platinum-containing therapy; Known additional malignancy that is progressing or requires active treatment; Other protocol-defined Inclusion/Exclusion Criteria may apply; Known active CNS metastases and/or carcinomatous meningitis.